Burkitt Lymphoma

P1, N=42, Active, not recruiting, Acepodia Biotech, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Jul 2026

Herein, we report a rare occurrence of a double-hit lymphoma with plasmablastic features in a patient with a history of follicular lymphoma (FL) aberrantly expressing keratin in the transformed component posing a diagnostic conundrum. Immunohistochemistry and molecular work-up in conjunction with clinical history were essential in arriving at the correct diagnosis and thus illustrating a diagnostic pitfall.

In this contemporary POL series, clinicopathologic heterogeneity was prominent, and laboratory profiles frequently overlapped with ovarian malignancy work-up. Outcomes may be favorable among patients receiving timely, subtype-appropriate systemic treatment.

Following a protocol amendment to evaluate the efficacy of siltuximab as a first-line treatment of CRS, one patient received siltuximab with full resolution of CRS after two doses without needing additional anti-cytokine-directed therapies...This extended experience demonstrates that CD19.22.BBζ CAR T-cell therapy is safe and clinically active, particularly as a bridge to HSCT. Non-response was confined to patients with non-CNS EMD, highlighting the persistent challenge of effectively targeting EMD and informing the design of future CAR constructs.Trial registration numberNCT03448393.

This case establishes the shared clonal origin between AITL and BL arising in the setting of CH and provides additional biological insight into the development of B-cell lymphoma associated with AITL.

P1, N=34, Active, not recruiting, National Cancer Institute (NCI) | N=55 --> 34 | Recruiting --> Active, not recruiting

While functional assays were not performed in this study, previous reports indicate that immature neutrophils can exhibit tumor-promoting functions. Therefore, the observed shift in neutrophil profiles may reflect phenotypic changes associated with malaria exposure that could contribute to a permissive environment for BL.

DHL patients more frequently had gross internal necrosis and infiltrative patterns on the neck CT images than conventional DLBCL patients.

Using this model system, we show that LMP2A induces plasmablast differentiation, increases expression of genes involved in lymphocyte mobility and trafficking and enhances tumor invasiveness in vivo. This new model system can thus be used to define roles of viral and cellular proteins in EBV-induced human GCB-derived lymphomas that lack EBNA2 expression.

Pediatric lymphoma in Jordan is most often diagnosed at an advanced stage, particularly NHL. Advanced NHL is associated with increased mortality. Early diagnosis, targeted therapy implementation, and incorporation of biomarkers such as LDH and CRP are urgently needed to improve risk assessment and patient outcomes.

We present the first case of a TP53 mutation from non-carrier parents affecting both mother and child to date. We describe the pathogenic variant and the possible mechanism underlying the co-occurrence of the proband's LFS and her mother's gestational choriocarcinoma.

PREG significantly attenuated MTX-induced pulmonary injury in this experimental model, as demonstrated by improved histopathological findings and reduced expression of inflammatory and endothelial activation markers, including COX-2, IL-6, and VCAM-1. These results provide tissue-level evidence supporting the potential protective effects of PREG against MTX-associated lung injury. However, oxidative stress parameters, functional pulmonary assessments, and intracellular signaling pathways were not directly evaluated in the present study. Therefore, the findings should be interpreted as morphological and hypothesis-generating evidence. Further investigations incorporating molecular, biochemical, and functional analyses are required to clarify the underlying mechanisms and to determine the translational relevance of these observations.